

June 23, 2008

**For further information
please contact:**

Joern Aldag
President &
Chief Executive Officer

+49.(0)40.560 81-242
+49.(0)40.560 81-333 Fax
joern.aldag@evotec.com

Anne Hennecke
Senior Vice President,
Investor Relations &
Corporate Communications

+49.(0)40.560 81-286
+49.(0)40.560 81-333 Fax
anne.hennecke@evotec.com

Evotec AG
Schnackenburgallee 114
22525 Hamburg
Germany
www.evotec.com

Evotec to Present at the Piper Jaffray Third Annual Europe Conference in London

Hamburg, Germany – Evotec AG (Frankfurt Stock Exchange: EVT, NASDAQ: EVTC) today announced that Jörn Aldag, President & CEO and Dr John Kemp, Chief Research & Development Officer will present at the Piper Jaffray Third Annual Europe Conference in London.

Date: Tuesday, June 24, 2008
Time: 04.20 pm BST (05.20 pm CET/11.20 am EDT)
Venue: Andaz Hotel, London, UK

A live webcast of the presentation will be accessible through the Evotec website at www.evotec.com - Investors. A replay will be available at www.evotec.com – Investors - Webcasts.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programs and through research collaborations, it is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries. In proprietary projects, Evotec specializes in finding new treatments for diseases of the Central Nervous System. Evotec has three programs in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABA_A receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation. Evotec's proprietary preclinical research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Evotec has worldwide collaboration and license agreements with Pfizer to research, develop and commercialize small molecule vanilloid receptor (VR1) antagonists. For additional information please go to www.evotec.com.